Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders.
Humans
HIV Infections
/ drug therapy
Female
Male
CD4 Lymphocyte Count
Adult
Prospective Studies
Immune Reconstitution
Middle Aged
Viral Load
CD4-Positive T-Lymphocytes
/ immunology
Anti-HIV Agents
/ therapeutic use
Apoptosis
/ drug effects
Treatment Outcome
Antiretroviral Therapy, Highly Active
T-Lymphocyte Subsets
/ immunology
Autophagy
/ drug effects
HIV-1
CD4+ T lymphocyte
HIV
albuvirtide
incomplete immune reconstitution
intensification
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
03
2024
accepted:
24
05
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
epublish
Résumé
Incomplete immune recovery in people living with HIV/AIDS (PLWHA) remains an important clinical challenge with the lack of an effective strategy currently available to restore their T-cell immune response. This study aimed to evaluate the effect of Albuvirtide (ABT) on immune recovery in immunological non-responders (INRs) and attempted to explore potential mechanisms of ABT on the functionality of immune cells. In this prospective, open-label, controlled clinical study, participants with incomplete immune reconstitution (continuous ART over 5 years and CD4 Both groups (n=25 each) were comparable in age, gender, and ART duration. At week 12, CD4 Significant CD4
Sections du résumé
Background
UNASSIGNED
Incomplete immune recovery in people living with HIV/AIDS (PLWHA) remains an important clinical challenge with the lack of an effective strategy currently available to restore their T-cell immune response. This study aimed to evaluate the effect of Albuvirtide (ABT) on immune recovery in immunological non-responders (INRs) and attempted to explore potential mechanisms of ABT on the functionality of immune cells.
Methods
UNASSIGNED
In this prospective, open-label, controlled clinical study, participants with incomplete immune reconstitution (continuous ART over 5 years and CD4
Results
UNASSIGNED
Both groups (n=25 each) were comparable in age, gender, and ART duration. At week 12, CD4
Conclusion
UNASSIGNED
Significant CD4
Identifiants
pubmed: 38975330
doi: 10.3389/fcimb.2024.1397743
pmc: PMC11227255
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1397743Informations de copyright
Copyright © 2024 Fan, Hu, Li, Ding, Liu, Yu, Hu, Su, Li, Yu, Xie, Zhao and Ma.
Déclaration de conflit d'intérêts
The authors SY, YuL, DX, MH was/were employed by Frontier Biotechnologies Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest